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Abstract
Background—During spring 2014, two large influenza outbreaks occurred among cruise ship 
passengers and crew on trans-hemispheric itineraries.
Methods—Passenger and crew information for both ships was obtained from components of the 
ship medical records. Data included demographics, diagnosis of influenza-like illness (ILI) or 
acute respiratory illness (ARI), illness onset date, passenger cabin number, crew occupation, 
influenza vaccination history, and rapid influenza diagnostic test (RIDT) result, if performed.
Results—In total, 3.7% of passengers and 3.1% of crew on Ship A had medically attended acute 
respiratory illness (MAARI). On Ship B, 6.2% of passengers and 4.7% of crew had MAARI. In 
both outbreaks, passengers reported illness prior to the ship’s departure. Influenza activity was low 
in the places of origin of the majority of passengers and both ships’ ports of call. The median age 
of affected passengers on both ships was 70 years. Diagnostic testing revealed three different co-
circulating influenza viruses [influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B] on 
Ship A and one circulating influenza virus (influenza B) on Ship B. Both ships voluntarily 
reported the outbreaks to the Centers for Disease Control and Prevention (CDC) and implemented 
outbreak response plans including isolation of sick individuals and antiviral treatment and 
prophylaxis.
Conclusions—Influenza activity can become widespread during cruise ship outbreaks and can 
occur outside of traditional influenza seasons. Comprehensive outbreak prevention and control 
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plans, including prompt antiviral treatment and prophylaxis, may mitigate the impact of influenza 
outbreaks on cruise ships.
Respiratory illness accounts for up to 29% of recorded illnesses on cruise ships,1 and cruise 
ship influenza outbreaks have been previously reported worldwide.2–5 Although influenza 
seasonality typically corresponds to winter months in temperate areas of the Northern and 
Southern Hemispheres,6 cruise ship destinations can include tropical areas where influenza 
activity lacks well-defined seasonality.6,7 Additionally, cruise ship environments, which 
often accommodate many travelers in partially enclosed settings, may facilitate influenza 
transmission.
Between March 15 and April 5, 2014, two cruise ships reported large outbreaks of medically 
attended acute respiratory illness (MAARI) among passengers and crew to the Centers for 
Disease Control and Prevention (CDC). MAARI includes cases of influenza-like illness 
(ILI) [defined as temperature of ≥100∘F (≥37.8°C)], oral or equivalent, and cough and/or 
sore throat, without a known cause other than influenza; and acute respiratory illness (ARI) 
(defined as cough and/or sore throat, without a known cause other than influenza). Both 
cruises originated in South America and terminated in Los Angeles, USA, following 17-day 
itineraries, which included eight ports of call at destinations in Chile, Peru, Costa Rica, 
Nicaragua, and Mexico. Low levels of influenza activity were reported in those areas during 
both voyages.8,9 As a result of the illnesses among passengers and crew, both ships activated 
their respiratory illness outbreak response plans.
Methods
Passenger and crew information for both ships was obtained from components of the ship 
medical records released to the CDC Los Angeles Quarantine Station. Data included 
demographics, diagnosis of ILI or ARI, illness onset date, passenger cabin number, crew 
occupation, influenza vaccination history, and rapid influenza diagnostic test (RIDT) result, 
if performed. For a subset of persons with MAARI, influenza testing was conducted using 
the CDC Human Influenza Real-Time Reverse-Transcription Polymerase Chain Reaction 
(rRT-PCR) assay or Luminex xTAG multiplex respiratory viral panel (Luminex Corporation, 
Toronto, Canada). Laboratory-confirmed influenza was defined as a positive RIDT result or 
a positive rRT-PCR test, if performed.
Both ships used questionnaires to identify passengers with respiratory illness symptoms 
upon embarkation and voluntarily reported ILI outbreaks to CDC using established 
methods.10 CDC defines a maritime ILI outbreak as exceeding a threshold of 1.38 cases per 
1,000 traveler-days. Initial rapid influenza diagnostic testing for passengers and crew 
members was ordered independently at the discretion of the cruise ship’s medical staff. CDC 
was consulted for outbreak prevention and control recommendations; cruise ship staff were 
responsible for implementing prevention and control measures.
Results
Ship A traveled from March 15 to April 1, 2014. Ship A entered service in the early 2000s 
and carried 2,595 passengers and 1,057 crew during the current voyage. Illness onset for the 
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first case of laboratory-confirmed influenza during this voyage occurred in a passenger from 
the UK 5 days before the ship’s departure date (Day 0) (Figure 1). Nine additional 
laboratory-confirmed influenza cases occurred in passengers who reported having symptoms 
prior to Day 0. The cumulative passenger ILI rate (2.70) exceeded the outbreak threshold on 
Day 0. In total, Ship A identified 97/2,595 (3.7%) passengers with MAARI (Table 1). The 
country of origin with the highest proportion of affected passengers (46/97, 47.0%) was the 
United States. The median age of passengers with MAARI was 70 years (range 6–89 years); 
33/95 (34.7%) had comorbid risk factors for influenza complications; 22/97 (22.7%) 
reported sharing a cabin with another ill passenger, and 65/97 (67.0%) reported having 
received an influenza vaccination. Of 54 passengers tested, 31 (57.0%) had laboratory-
confirmed influenza (20 by RIDT and 11 by rRT-PCR). Illness onset for the first laboratory-
confirmed case among the crew occurred on the day after the ship’s departure date (Day 1) 
(Figure 1), and the cumulative crew ILI rate (1.89) exceeded the outbreak threshold on Day 
2. Of 1,057 crew members, 33 (3.1%) had MAARI (Table 2). The majority of crew members 
with MAARI (57.6%) had occupations in food service. Overall crew influenza vaccination 
coverage on Ship A was 90%, and 31/33 (93.9%) crew with MAARI reported receipt of 
influenza vaccination. Of the crew tested, four (40%) had laboratory-confirmed influenza 
(three by RIDT and one by rRT-PCR). Overall, rRT-PCR testing performed by CDC 
revealed three different co-circulating influenza viruses among passengers and crew (five 
influenza A(H1N1)pdm09, four influenza A(H3N2), and three influenza B viruses).
Ship B traveled from March 20 to April 5, 2014. Ship B entered service in the mid-2000s 
and carried 2,987 passengers and 1,157 crew during the current voyage. Two passengers 
from the United States and Australia with laboratory-confirmed influenza reported 
symptoms on Day 0; however, additional passengers and crew also reported having 
respiratory symptoms before departure (Figure 2). The cumulative passenger ILI rate (2.00) 
exceeded the outbreak threshold on Day 0. In total, Ship B identified 187/2,987 (6.2%) 
passengers with MAARI (Table 1). The highest proportion of affected passengers (108/187, 
58.0%) was from the United States. The median age of passengers with MAARI was 70 
years (range 29-91 years); 60 (32.1%) reported sharing a cabin with another ill passenger, 
and 154 (82.8%) reported receipt of influenza vaccination. Of 45 passengers tested, 10 
(22.0%) had laboratory-confirmed influenza (seven by rRT-PCR and three by RIDT). Ship B 
identified 54/1,157 (4.7%) crew with MAARI (Table 2) and the cumulative crew ILI rate 
never exceeded the outbreak threshold. The majority of the affected crew (38.9%) had 
occupations in food service. Overall crew influenza vaccination coverage on Ship B was 
95.5%; all crew with MAARI reported receipt of influenza vaccination. Of six crew tested, 
one (17.0%) was positive by RIDT. The Los Angeles County Public Health Laboratory 
identified seven influenza B viruses among passengers using the Luminex xTAG multiplex 
respiratory viral panel.
Outbreak control measures on both ships included active surveillance for MAARI in crew 
and passengers to identify incident cases, isolation of passengers and crew with MAARI, 
empiric antiviral treatment for confirmed and suspected cases of influenza, 
chemoprophylaxis of all close case contacts (eg, sharing a room with a symptomatic 
individual), and other nonpharmaceutical measures such as improved hand hygiene.
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Discussion
We report two large influenza outbreaks among passengers and crew on cruise ships with 
similar itineraries during spring 2014. The proportion of persons with MAARI on Ship A 
(3.5%) and Ship B (5.8%) suggests that widespread influenza activity occurred during each 
voyage, prompting voluntary reporting. These outbreaks highlight the usefulness of 
respiratory disease surveillance and several issues important to influenza preparedness and 
response activities on cruise ships.
Although cruise ships destined for the United States are required to report novel or 
reemergent influenza viruses with pandemic potential among passengers or crew to CDC 
under the Foreign Quarantine Regulations (42 CFR Part 71), reporting of seasonal influenza 
is not required.7 Since respiratory disease outbreaks on cruises may be frequent,1,7,11 CDC 
has developed a cruise ship ILI surveillance mechanism in conjunction with cruise ships to 
augment reporting.7 Unlike CDC’s Vessel Sanitation Program,12 which requires reporting of 
gastrointestinal illness in cruise ships carrying 13 or more passengers and with a foreign 
itinerary with US ports,12 reporting of suspected or confirmed outbreaks of seasonal 
influenza on cruise ships is voluntary.13 Per CDC’s ILI guidance, surveillance for influenza 
on cruise ships involves recording all ILI cases or confirmed cases of influenza among 
passengers and crew on reporting logs and calculating ILI thresholds.7,13 If a cruise ship 
voluntarily reports an outbreak, CDC can provide guidance on prevention and control 
measures. Similarly, in Europe, the European Union SHIPSAN TRAINET Project has 
developed a similar set of maritime influenza outbreak prevention and response guidelines, 
which includes logging cases of ILI as part of routine surveillance as well as plans for 
treatment and chemoprophylaxis in the event of an outbreak.14 The Maritime Declaration of 
Health, a component of the World Health Organization’s 2005 International Health 
Regulations, is another mechanism by which cruise ships can report illnesses to health 
authorities in countries of disembarkation.15 As occurred in our two outbreaks, routine ILI 
surveillance enabled cruise ship medical staff to detect their ongoing influenza outbreaks 
quickly and to report the outbreaks to CDC, which allowed a collaborative approach to 
rapidly implementing outbreak response activities.
Both outbreaks occurred during periods of low influenza activity in areas included in the 
ships’ trans-hemispheric journeys8,9 suggesting that maritime cruises may be vulnerable to 
influenza outbreaks outside of the traditional influenza seasons of the countries in their 
itineraries.16 Influenza outbreaks on cruise ships have previously been reported as occurring 
during and outside of traditional influenza seasons.2,17 Furthermore, since cruise ships 
frequently carry passengers from many different countries,5 it may be prudent to consider 
their influenza “season” to be year-round, regardless of the itinerary. The outbreaks 
described in this report are similar to previous cruise ship outbreaks in that both were large 
and one involved multiple co-circulating strains of influenza.2 These findings underscore 
how cruise ship environments can facilitate influenza outbreaks that may not occur in other 
travel settings. First, cruise ships can facilitate respiratory virus transmission because 
passengers and crew are in close contact for extended periods of time in partially enclosed 
areas.4,14 Second, because travel includes frequent layovers at ports of call where new crew 
and passengers can board, cruise ships allow introduction of new susceptible persons (and 
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perhaps new infected persons as well) into this enclosed environment at multiple points 
during their voyages.
Influenza outbreaks on cruise ships can resemble outbreaks in long-term care facilities 
(LTCFs) — in both settings, outbreaks can be extensive and involve high-risk populations. 
Similar to LTCFs, cruise ships often carry passengers at increased risk for influenza 
complications — persons aged ≥65 and with medical comorbidities.2 Therefore, cruise ship 
outbreak response strategies should reflect the multifaceted nature of outbreak management 
plans in LTCFs and communities.5,18 The primary components of outbreak management on 
cruise ships involve surveillance, case identification, and treatment and response measures. 
Routine ILI surveillance can identify potential cases of respiratory illness among passengers 
and crew. Diagnostic testing is challenging in a cruise ship setting and often relies on point-
of-care platforms, such as RIDTs, which both Ship A and Ship B employed.19 Although 
RIDTs have poor sensitivity,20 which may produce false-negative results, the finding of 
positive RIDT results in the setting of multiple cases of ILI within a 72-hour period is likely 
indicative of an influenza outbreak in a cruise ship setting, which necessitates prompt 
response.13,18 After cruise ship outbreaks are identified, recommended control measures 
include isolation of ill persons, antiviral treatment of confirmed and suspected cases, and 
chemoprophylaxis of high-risk contacts13 — recommendations similar to guidance for 
influenza outbreak management in LTCFs.5,18 Prompt influenza antiviral treatment can 
prevent complications among hospitalized and high-risk ambulatory patients with 
influenza.21,22 Additionally, antiviral chemoprophylaxis can limit transmission to 
noninfected individuals; it is used in LTCFs to prevent ongoing transmission during 
influenza outbreaks, and the same reasoning can apply for cruise ship outbreaks.18
Prevention and control of influenza outbreaks during maritime travel can involve 
complexities not commonly seen in other settings. For example, identifying illnesses may 
prove challenging if some passengers withhold symptoms because they fear travel may be 
curtailed or denied. Although both ships in this report used questionnaires to identify ill 
passengers at embarkation, 17 confirmed influenza cases with symptom onset prior to or on 
the day of departure were later identified, only after passengers eventually sought care for 
their illnesses. Cruise ship staff should strongly encourage passengers who elect to travel 
while ill, or who become ill en route, to report symptoms promptly so that they may receive 
appropriate medical treatment and that, if appropriate, the ship’s outbreak response plan may 
be employed to mitigate illness among other passengers and crew. Additionally, cruise ship 
influenza outbreaks have been shown to be prolonged if newly susceptible passengers join 
the cruise ship at different destinations at ports along the itinerary.17 Since we do not know 
if new passengers or crew embarked along the itinerary for either ship in this report, we are 
unable to assess whether this mechanism contributed to either of the outbreaks we describe.
Our findings are limited because we were unable to interview all passengers and crew; thus, 
both outbreaks we describe represent only medically attended illnesses. Previous studies 
have shown that self-administered passenger surveys often identify additional cases.5 
Therefore, both outbreaks may have been larger than suggested by our data. Additionally, 
our findings do not include data from previous or subsequent cruises for either ship, so we 
were unable to evaluate events not reported during their current voyages. Finally, we were 
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unable to evaluate the implementation of our active surveillance or treatment 
recommendations during the outbreaks.
The potential impact of influenza outbreaks on cruise ships is large as >70 million 
passenger-days of travel are booked annually on North American cruises.23 Often isolated 
from land-based medical assistance, cruise ships may need to rely on staff and supplies on 
hand for outbreak control during their voyages. As part of an overall prevention plan, cruise 
ship medical staff should vaccinate crew members prior to departure and anticipate surges in 
demand for medical care that an outbreak may precipitate. This includes ensuring that 
antiviral medication supplies are sufficient to control outbreaks involving large numbers of 
persons. Passengers should also be encouraged to seek medical consultation prior to travel to 
determine specific medical care needs and to receive an annual influenza vaccination. 
Collaboration between public health and cruise ship medical staff to create response 
strategies may also help overcome the challenges in managing influenza outbreaks during 
maritime travel.
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Figure 1. 
Epidemic curve of confirmed influenza cases and cases of medically attended acute 
respiratory illness (MAARI) among passengers and crew on Ship A, March 15 to April 1, 
2014. Medically attended acute respiratory illness includes cases of influenza-like illness 
and acute respiratory illness. Day 0 corresponds to March 15, 2014, which was the day of 
departure for Ship A, C corresponds to a confirmed case of influenza in a crew member.
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Figure 2. 
Epidemic curve of confirmed influenza cases and cases of medically attended acute 
respiratory illness (MAARI) among passengers and crew on Ship B, March 20 to April 5, 
2014. Medically attended acute respiratory illness includes cases of influenza-like illness 
and acute respiratory illness, Day 0 corresponds to March 20, 2014, which was the day of 
departure for Ship A, C corresponds to a confirmed case of influenza in a crew member.
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Table 1
Cases of medically attended acute respiratory illness*(MAARI) and characteristics of confirmed influenza 
cases among passengers on Ships A and B
Ship A: n (%) Ship B: n (%)
Passengers 2,595 2,987
MAARI (n/passengers) 97 (3.7) 187 (6.2)
Age (median, range)
 (n=MAARI)
70 (6–89) 70 (29–91)
Male (n/MAARI) 38/97 (39.2) 80/186 (43.0)
Comorbid risk factor†
 (n/MAARI)
33/95 (34.7) Data unavailable
Shared cabin with ill
 passenger
 (n/MAARI)
22/97 (22.7) 60/187 (32.1)
Received influenza
 vaccination
 (n/MAARI)
65/97 (67.0) 154/186 (82.8)
Passengers tested
 (n/MAARI)
54/97 (55.7) 45/187 (24.1)
Laboratory-confirmed
 influenza (n/tested)
31/54 (57.4) 10/45 (22.2)
*
Medically attended acute respiratory illness includes cases of influenza-like illness and acute respiratory illness.
†Comorbid risk factors include persons with chronic pulmonary conditions (including asthma); cardiovascular disease (except hypertension alone); 
renal, hepatic, or hematologic (including sickle cell) disease; metabolic disorders (including diabetes mellitus); or neurologic and 
neurodevelopment conditions [including disorders of the brain, spinal cord, peripheral nerve, and muscle, such as cerebral palsy, epilepsy (seizure 
disorders), stroke, intellectual disability (mental retardation), moderate to severe developmental delay, muscular dystrophy, or spinal cord injury]; 
persons with immunosuppression, including that caused by medications or by human immunodeficiency virus infection.
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Table 2
Cases of medically attended acute respiratory illness*(MAARI) and characteristics of confirmed influenza 
cases among crew on Ships A and B
Ship A: n (%) Ship B: n (%)
Crew 1,057 1,157
MAARI (n/crew) 33 (3.1) 54 (4.7)
Age (median, range)
 (n=MAARI)
33 (23–49) 31.5 (22–61)
Male (n/MAARI) 22/33 (66.7) 37/54 (68.5)
Comorbid risk factor†
(n/MAARI)
0/33 (0) Data unavailable
Received influenza
 vaccination
 (n/MAARI)
31/33 (93.9) 54/54 (100)
Occupation category (n/MAARI)
 Food service 19/33 (57.6) 21/54 (38.9)
 Entertainment 4/33 (12.1) 6/54 (11.1)
 Accommodation 2/33 (6.1) 10/54 (18.5)
 Other 8/33 (24.2) 17/54 (31.5)
Crew tested
 (n/MAARI)
10/33 (30.3) 6/54 (11.1)
Laboratory-confirmed
 influenza (n/tested)
4/10 (40.0) 1/6 (16.7)
*
Medically attended acute respiratory illness includes case of influenza-like illness and acute respiratory illness.
†Comorbid risk factors include persons with chronic pulmonary conditions (including asthma); cardiovascular disease (except hypertension alone); 
renal, hepatic, or hematologic (including sickle cell) disease; metabolic disorders (including diabetes mellitus); or neurologic and 
neurodevelopment conditions [including disorders of the brain, spinal cord, peripheral nerve, and muscle, such as cerebral palsy, epilepsy (seizure 
disorders), stroke, intellectual disability (mental retardation), moderate to severe developmental delay, muscular dystrophy, or spinal cord injury]; 
persons with immunosuppression, including that caused by medications or by human immunodeficiency virus infection.
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